Research Progress on the Mechanism of PMDD

doi:10.3969/j.issn.2095-1396.2019.06.008

Abstract

Abstract:

Premenstrual dysphoria（PMDD）often occurs in women of appropriate age. The pathogenesis of PMDD is not clear，which results in poor efficacy and serious side effects of clinical drugs. In this paper，the pathogenesis and therapeutic drugs of PMDD in traditional Chinese medicine and modern medicine are reviewed，in order to better promote the treatment of PMDD and related new drug research and development.

Key words: mechanism of PMDD, stagnation of liver qi, neurotransmitter, drug therapy of PMDD

CLC Number:

R339.2

XIA Xiao-wen，SONG Chun-hong，QIAO Ming-qi, et al. Research Progress on the Mechanism of PMDD[J]. Acta Neuropharmacologica, DOI: 10.3969/j.issn.2095-1396.2019.06.008.

References

[1] Suman Kadian, Shaughn O Brien. Classification of premenstrual disorders asproposed by the International Society for Premenstrual Disorders[J]. Menopause, 2012, 18(2) : 43-47．
[2] Ran Jin, Le Ngoc-Anh, Liu Shu-ling L, et al. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD[J]. J Clinical Endocrinology & Metabolism, 2012, 97(7):1088-98.
[3] Elias Pean, Sigrid Klaar, Eva Gil Berglund, et al. The EuroPean medicines agency review of eribulin for the treatment of Patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal Products for human use [J]. Clinical Cancer Research, 2012, 18(17):4491-7.
[4]张震，纪立金，许晓芬．经前烦躁症的研究进展[J］．广西医学，2017，39(6):867-870．
[5] C Laurel Franklin，Amanda M Raines，Jessica L Chambliss，et al．Examining various subthreshold definitions of PTSD using the Clinician Administered PTSD Scale for DSM-5［J］.J Affect Disord, 2018, 234: 256-260．
[6] 鞠佃君．经前平颗粒治疗PMDD肝气逆证的疗效研究［D］.济南:山东中医药大学，2016.
[7] Franklin C L，Ｒaines A M，Chambliss J L，et al．Examining various subthreshold definitions of PTSD using the Clinician Administered PTSD Scale for DSM-5［J］.J Affect Disord，2018，234: 256-260
[8]鞠佃君．经前平颗粒治疗PMDD肝气逆证的疗效研究［D］.济南:山东中医药大学，2016.
[9]郑莉明,史亚飞,吴皓萌,等.中枢5-HT能系统在早发性抑郁中的作用研究[J].中国药理学通报,2015,v.31(1):19-23.
[10]郑莉明,史亚飞,吴皓萌,等.中枢5-HT能系统在早发性抑郁中的作用研究[J].中国药理学通报,2015(01):19-23.
[11]李永超,彭亮,王高华,等.炎性因子、皮质醇、5-羟色胺与抑郁严重程度关系的初步研究[J].国际精神病学杂志,2015,42(06):6-9.
[12] Charles B Nemeroff. Recent advances in the neurobiology of depression[J]. Psychopharmacology Bulletin, 2002, 36 (Suppl 2):6.
[13] Gian Marco Leggio, Salvatore Salomone, Claudio Bucolo, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression[J]. European J Pharmacology, 2013, 719(3):25-33.
[14] Frank P Bymaster, Robert K Mcnamara, Pierre V Tran. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission[J]. Expert Opin Investig Drugs, 2003, 12(4):531-43.
[15] Claus Braestrup, Henning Andersen, Axel Randrup. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation[J]. European J Pharmacology, 1975, 34(1):181.
[16]陈小平.抑郁症患者中医不同辨证分型脑内5-HT、NE、DA神经递质变化规律的研究[D]. 北京：北京中医药大学, 2014.
[17]尹红蕾.GABA-谷氨酸系统、糖皮质激素受体相关基因与自杀行为的关联研究[D].广州：南方医科大学,2017.
[18] Younglim Lee, Denise Gaskins, Amit Anand, et al. Glia mechanisms in mood regulation: a novel model of mood disorders[J]. Psychopharmacology, 2007, 191(1):55-65.
[19]杨辉,许丽娟.谷氨酸N-甲基-D-天冬氨酸受体拮抗剂的抗抑郁作用研究进展[J].中国新药与临床杂志,2011,(12):891-894.
[20]翁小娟.抑郁症患者血浆谷氨酸、γ氨基丁酸水平及与抑郁程度的关系[D].杭州：浙江大学, 2011.
[21] Kinga Satat, Katarzyna Kulig, Justyna Gajda, et al. Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice[J]. Pharmacology Biochemistry & Behavior, 2013, 110(8):145.
[22] Inger Sundstrom, Donald Ashbrook, Torbjorn Bckstrm. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study［J］. Psychoneuroendocrinology, 1997, 22 (1): 25-38．
[23] Wang Zhen-song, Zhang Ai-ying, Zhao Bin, et al. GABA+ levels in postmenopausal women with mild-to-moderate depression: A preliminary study[J]. Medicine, 2016, 95(39):e4918.
[24] Arianna Di Lorenzo, Seyed Fazei Nabavi, Antoni Sureda, et al. Antidepressive-like effects and antioxidant activity of green tea and GABA green tea in a mouse model of post-stroke depression[J]. Molecular Nutrition & Food Research, 2016, 60(3):566-579.
[25]何婷.慢性应激性抑郁发生与海马Glu和GABA水平变化及其受体机制[D].西安：陕西师范大学,2011.
[26]田园，张惠云．自香丹胶囊对经前期综合征肝气逆证大鼠下丘脑GABAARβ2亚基分布及表达的影响［J］.山东中医杂志，2010，29(7):479－481．
[27] Ruth M Mckernan, Paul J Whiting. Which GABAA-receptor subtypes really occur in the brain? [J] Trends Neurosci, 1996, 19(4): 139–143.
[28] Uwe Rudolph, Florence Crestani, Dietmar Benke, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes[J]. Nature, 1999, 401: 796–800.
[29] Florence Crestani, James R Martin, Hanns Mo¨hler, et al. Mechanism of action of the hypnotic zolpidem in vivo[J]. Br J Pharmacol, 2000, 131:1251–1254.
[30] McKernan R M, Rosahl T W, Reynolds D S, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype[J]. Nat Neurosci, 2000, 3: 587–592.
[31] Low K, Crestani F, Keist T, et al. Molecular and neuronal substrate for the selective attenuation of anxiety[J]. Science, 2000, 290(5489): 131–134.
[32] David S Reynolds, Ruth M McKernan, Gerard Dawson GR. Anxiolytic-like action of diazepam: which GABA(A) receptor subtype is involved? [J]. Trends Pharmacol Sci, 2001, 22(8): 402–403.
[33] Rebecca Dias, Wayne Sheppard, Rosa Fradley, et al. Evidence for a significant role of a3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines[J]. J Neurosci, 2005, 25(46):10682–10688.
[34] Atack J R, Hutson P H, Collinson N, et al. Anxiogenic properties of an inverse agonist selective for a3 subunit-containing GABAA receptors[J]. Br J Pharmacol, 2005, 144(3): 357–366.
[35] Neil Collinson, Frederick M Kuenzi, Wolfgang Jarolimek, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the a5 subunit of the GABAA receptor[J]. J Neurosci, 2002, 22(13): 5572–5580
[36] Albert M I Barth, Isabella Ferando. Ovarian cycle-linked plasticity of δ-GABAA receptor subunits in hippocampal interneurons affects γ oscillations in vivo[J]. Front Cell Neurosci, 2014, 8: 222.
[37] Jamie L Maguire, Brandon M Stell, Mahsan Rafizadeh, et al. Ovarian cycle linked changes in GABAA receptors mediating tonic inhibition alter seizure susceptibility and anxiety Nat[J]．Neurosci, 2005, 8(6) : 797-804
[38] Hector Romo-Parra, Peter Blaesse, Ludmila Sosulina, et al. Neurosteroids increase tonic GABAergic inhibition in the lateral section of the central amygdala in mice[J]. J Neurophysiol, 2015, 113 (9) : 3421-3431
[39] Dietmar Benke, Claudia Michel, Hanns Moehler. GABAA receptors containing the α 4-subunit: prevalence, distribution, pharmacology, and subunit architecture in situ[J]. J Neurochem, 1997, 69(2):806-814.
[40] Smith Sheryl S, Gong Qi-hua, Hsu Fu-chun, et al. GABAA receptor α 4 subunit suppression prevents withdrawal properties of an endogenous steroid[J]. Nature, 1998, 392(6679):926-929.
[41] Zhou Lin, Zong Lu, Zhang Lu-lu, et al. Association of single nucleotide polymorphisms in the promoter of GABA_A receptor β2 subunit gene with schizophrenia[J]. J Southern Medical University, 2015, 35(2):256.
[42] Rigil K Yeung, Zheng-Hua Xiang, Shui-Ying Tsang, et al. Gabrb2-knockout mice displayed schizophrenia-like and comorbid phenotypes with interneuron–astrocyte–microglia dysregulation[J]. Translational Psychiatry, 2018, 8(1):128.
[43] Niall W Duncan, Christine Wiebking, Georg Northoff. Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans—A review of multimodal imaging studies[J]. Neuroscience & Biobehavioral Reviews, 2014, 47(1):36-52.
[44] Sheryl S Smith, Gong Qi-hua, Hsu Fu-chun, et al. GABAA receptor α 4 subunit suppression prevents withdrawal properties of an endogenous steroid[J]. Nature, 1998, 392(6679):926-929.
[45] 李艺杰,王美艳,薛玲,等.舒郁胶囊对PMDD肝气郁证模型大鼠Cav1.2介导的CaM/CaMKⅡ信号通路的影响[J].中国实验方剂学杂志,2018,24(10):130-136.
[46] 牟翔宇,郭英慧,孙文君,等.柴胡配伍白芍治疗PMDD肝气郁证的研究进展[J].中国实验方剂学杂志,2018,24(20):192-199.
[47] 张崇燕，唐永鑫，曾南，等．逍遥散及其组方对行为绝望抑郁模型小鼠的影响[J]．成都中医药大学学报，2009,32(2):51-53．
[48]李鹏．舒郁胶囊联合氟西汀治疗抑郁症(轻、中度)肝气郁证疗效观察及对HPA轴影响机制研究[D］.济南: 山东中医药大学，2016．
[49]孙文君，乔明琦，王海军，等.关于经前烦躁障碍症亚型的理论探讨[J]，辽宁中医杂志，2017,44(10):2071-2073．
[50]鲁玉强，杨欢．柴胡类经方治疗抑郁症的研究进展[J]．光明中医，2017，32(17):2591-2594．
[51]薛晓丽．柴胡疏肝散加减治疗肝郁气滞型经前期综合征的临床观察［D］．哈尔滨:黑龙江中医药大学，2017．
[52] 张宝宝，姚菁，金海燕,等．柴胡-白芍醇提液抗抑郁和保肝作用实验研究[J]．甘肃中医药大学学报，2016，33(6):10-15．
[53] 陈彦,王晋艳,辛然,等．柴胡皂苷对芍药苷在Caco-2细胞模型中吸收转运的影响[J]．中国中药杂志，2012，37(12):1850-1854．
［54］朱永智，陈鸿英，张桂贤，等．白芍与柴胡不同比例配伍白芍总苷及苯甲酸水煎出量的比较[J].天津中医药，2011，28(1):78-79．
[55] Mariel Marder, Alejandro C Paladini. GABAA-receptor ligands of flavonoid structure[J]. Curr Top Med Chem, 2002, 2(8): 853–867.
[56] Wang Feng, Michael Shing, Yan Huen, et al. Neuroactive flavonoids interacting with GABAA receptor complex[J]. Curr Drug Targets CNS Neurol Disord, 2005, 4(5):575–585.
[57]张嫱.舒郁胶囊与柴胡提取物对抑郁症肝气郁结证模型大鼠海马氨基酸类神经递质受体表达的影响[D].济南：山东中医药大学,2012.
[58]李伟,王景霞,葛阳,等.芍药苷对血虚肝郁证模型大鼠海马谷氨酸及其不同类型受体mRNA表达的影响[J].中华中医药杂志,2016(4):1241-1244.
[59]夏花.氯硝西泮联合帕罗西汀对酒依赖患者负性情绪及治疗效果的影响[J].世界中医药, 2015,10(a02): 1485-1486.
[60]毕斌.舍曲林与氯硝西泮联合治疗抑郁症的疗效分析[J].现代诊断与治疗,2016,27(6): 1045-1046.
[61]曹玉婷.西酞普兰联合氯硝西泮与单用西酞普兰治疗抑郁症的临床疗效[J].当代医学, 2016, 22(22): 128-129.
[62]陈志明.度洛西汀治疗64例抑郁症伴躯体疼痛障碍临床对照观察[J]，医药前沿，2016，6(1):104－105．
[63]林培珺，毛高峰．米氮平对脑梗死后抑郁症患者的治疗效果及安全性观察[J]．神经损伤与功能重建，2016,11(03)：273-274．
[64]王彩宁，温爱萍，田欣，等．应用氟哌噻吨美利曲辛治疗抑郁症疗效及脑电图变化研究[J].山西医药杂志，2016，45(17) :2044－2045．
[65]蒋胜菊.米氮平、舍曲林、度洛西汀在治疗伴躯体疼痛症状抑郁症患者中的临床疗效[J].医学理论与实践,2019,32(15):2378-2379.